top of page
of novel formulations
There is much research focused on developing new strategies to increase the vitreous residence times of macromolecular drugs to decrease the frequency of intravitreal injections.
The PK-Eye™ is for the evaluation and optimisation of novel ocular formulations and delivery systems for the vitreous. The PK-Eye™ can accelerate the development of longer-lasting therapeutic dosage forms during preclinical development that are needed to treat chronic blinding conditions.
Optimisation of a bevacizumab and a protein conjugate (PEG10-Fabrani) hydrogel formulation using the PK-Eye™
Awwad et al, Macromol Biosci. 2018; 18 (2):1700255
bottom of page